Related Experiment Video

Updated: Apr 15, 2026

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

12.0K

[Pharmacological treatment for diabetic macular edema]

Masanori Fukumoto, Tsunehiko Ikeda

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |March 28, 2015
    PubMed

    More Related Videos

    Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report10:24

    Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

    Published on: February 12, 2018

    10.9K
    Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization05:14

    Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

    Published on: August 11, 2023

    1.7K

    Related Concept Videos

    Open Angle Glaucoma: Treatment01:27

    Open Angle Glaucoma: Treatment

    In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
    Drugs such as carbonic anhydrase inhibitors, α2- and...
    1.1K
    Diabetes: Management and Pharmacotherapy01:15

    Diabetes: Management and Pharmacotherapy

    The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
    Insulin remains the cornerstone of treatment for most patients with type 1 and many...
    1.5K
    Angle Closure Glaucoma: Treatment01:28

    Angle Closure Glaucoma: Treatment

    Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
    1.7K
    Ophthalmic Drug Delivery Systems01:23

    Ophthalmic Drug Delivery Systems

    Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
    251
    Dipeptidyl Peptidase 4 Inhibitors01:23

    Dipeptidyl Peptidase 4 Inhibitors

    Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
    1.1K